NAVLIN Daily NewsCheckout Today’s News
Bidding in China's 12th round of volume-based procurement (VBP) begins July 31, covering 65 drugs. More than 450 companies have qualified to participateWhile the general bidding framework is the same this year, rules have been optimized to encourage rational bidding, refine volume allocation, stabilize the country's drug supply, and offer more reliable market expectations for drugmakersAnchor pricing was adjusted to prevent abnormally low bids from disrupting the system, and original drugs have a new chance to stay in the mix through bid revivals
U.S. President Donald Trump is looking to leverage tariffs against imported generic medicines in an effort to strengthen domestic productionIn a recent Truth Social post, President Trump said that beginning August 1, 2028, the U.S. will implement a tariff of 100% on imported generic pharmaceuticals for one year. After that, the tariff will increase to 200% "This is done in order to reshore generic pharmaceutical production into America, with a penalty to those companies that decide not to build plan and equipment within the stated period of time given to them," the post reads. "The objective of this policy is to protect the people of the United States"
Japan’s Cabinet has approved the Basic Policy on Economic and Fiscal Management and Reform 2026 (honebuto), identifying drug discovery and advanced medicine as strategic growth sectors and supporting expanded public-private investment, clinical-trial capacity and domestic pharmaceutical productionAgainst the backdrop of the U.S. most-favored-nation (MFN) policy and other overseas policy developments, the policy aims to create an environment in which necessary medicines are reliably launched in Japan. The government will also objectively review Japan’s cost-effectiveness assessment system, then use the findings to consider further revisions aimed at developing the system and reach a conclusionMeanwhile, the Japan Pharmaceutical Manufacturers Association (JPMA) welcomed the direction, saying: “We regard the explicit inclusion of a direction to further evaluate innovation in innovative new medicines, including appropriate value assessment at initial listing, as an important step forward”
Spain’s Council of Ministers has approved a new Draft Law on Medicines and Health Products, sending a wide-ranging overhaul of the country’s pharmaceutical rules to parliament after 16 months of consultation and legal reviewPresenting the Draft following Tuesday’s meeting of the Council of Ministers, Health Minister Mónica García acknowledged that the legislation was highly technical but said the legislation sought to answer how the National Health System (SNS) could finance more medicines and what should happen when a patient arrives at the pharmacy and the medication they need is unavailableThe first Draft was cleared in April 2025 for submission to the public hearing process. Since then, the government has examined thousands of representations from the pharmaceutical sector, which initially expressed concern about parts of the proposed reform. The text has also passed through the Council of State and expanded considerably during the process, growing from 146 to 159 articles. Some of its most contentious provisions were removed or modified, including the original proposal concerning selected prices, which evolved into the current dynamic pricing model
Last week, Germany passed the GKV Stabilization Act after it cleared the Bundestag and the Bundesrat. The plan doubles drugmaker discounts to 15.5% and extends a drug price freeze until 2030. Industry has pushed back on the Act, saying it jeopardizes access to innovation and weakens Germany as a location for investment Meanwhile, a new analysis has found that Denmark's confidential pharmacy pricing pilot failed to deliver the expected results in its first year Japan's Central Social Insurance Medical Council (Chuikyo) has begun discussions on the scope and methodology of the FY2027 off-year National Health Insurance (NHI) drug price revision
Ireland's National Center for Pharmacoeconomics (NCPE) became the first HTA agency to complete a national assessment for Novartis' Itvisma, undergoing an EU Joint Clinical Assessment (JCA), using the JCA report to inform its rapid review before the report's public releaseThe NCPE issued an unfavorable reimbursement recommendation, advising that Itvisma not be considered for reimbursement at the submitted price and did not recommend a full HTAIreland issued its national reimbursement recommendation only 16 days after EU marketing authorization and before the European Commission is expected to publish the JCA report in early August 2026
Novo Nordisk will launch Extensior, a lower-cost authorized copy of its diabetes medicine Ozempic (semaglutide), in South Africa on July 27 It will be launched through a partnership with healthcare company Acino in the same 0.25 mg, 0.5 mg, and 1 mg doses as Ozempic and will be priced below the branded product"Prices around this will be confirmed to the market next week. I can confirm that Extensior will be cheaper than (branded) semaglutide for use in type 2 diabetes," Sara Norcross, General Manager of Novo Nordisk South Africa, told Reuters
According to a report by Kun.uz, Uzbekistan lowered the reference price ceilings for 2,500 prescription medicines sold in pharmacies effective July 1, 2026, with price reductions of up to 50.1% across several major therapeutic categories under its state-regulated reference pricing systemThe Agency for the Development of the Pharmaceutical Industry spokesperson, Anvar Akabirov, said prices for antibiotics and antimicrobial medicines were reduced by up to 50.1%, cardiovascular diseases saw price cuts of up to 37%, while drugs affecting the nervous system became up to 40% cheaper. Prices for anti-inflammatory medicines and painkillers were reduced by as much as 42%Akabirov said pharmacies can no longer sell medicines covered by the revised reference prices under the previous price ceilings
The National Institute for Health and Care Excellence (NICE) has published its 2025–2026 Annual Report and Accounts, highlighting key achievements, operational improvements, and strategic priorities over the period from April 2025 to March 2026During the reporting period, NICE completed 98 medicine evaluations, recommending 66 medicines, terminating 25 appraisals, and issuing seven negative recommendationsThe report highlights faster guidance development, with medicines appraisals completed 30% faster and health technology guidance 9% faster since April 2024
Sun Pharma to launch its generic semaglutide injection in South Africa in the coming days for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise The launch follows approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market the product in the country"South Africa is the second market after India where Sun Pharma has received approval for generic semaglutide. This reflects our ability to develop complex generic medicines that meet the stringent quality standards across different markets," said Aalok Shanghvi, Chief Operating Officer, Sun Pharma
650+
+99%
<24
4,000+
24x7
99.5%
